Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor–positive advanced breast cancer

Despite advances in cytotoxic chemotherapy and targeted therapies, 5-year survival rates remain low for patients with advanced breast cancer at diagnosis. This highlights the limited effectiveness of current treatment options. An improved understanding of cellular functions associated with the devel...

Descripción completa

Detalles Bibliográficos
Autor principal: Beck, J Thaddeus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676614/
https://www.ncbi.nlm.nih.gov/pubmed/26675495
http://dx.doi.org/10.2147/OTT.S88037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676614/
https://www.ncbi.nlm.nih.gov/pubmed/26675495
http://dx.doi.org/10.2147/OTT.S88037

Ejemplares similares